ANGPTL4 is elevated in the vitreous humor of patients with proliferative diabetic retinopathy who do not respond to anti-VEGF therapy, suggesting a novel therapeutic target.
What is the role of ANGPTL4 in proliferative diabetic retinopathy compared to VEGF?
ANGPTL4 drives aberrant retinal lymphatic-like remodeling in proliferative diabetic retinopathy, representing a potential novel therapeutic target for patients resistant to anti-VEGF therapy.
Absolute Event Rate: 0% vs 0%
Some patients with proliferative diabetic retinopathy (PDR) have poor responses to anti-vascular endothelial growth factor (anti-VEGF) therapy. This situation highlights the need for additional therapeutic approaches. In proliferative diabetic retinopathy, what is the role of ANGPTL4 that differs from VEGF? We found that ANGPTL4 is elevated in the vitreous humor of patients with PDR who are poorly responsive to anti-VEGF therapy. ANGPTL4, particularly its C-terminal fragment, causes retinal lymphatic-like remodeling in diabetic mice. This study provides novel insights into the complex interplay between immune activation, neovascularization, and lymphatic-like remodeling in PDR. Our findings deepen our understanding of PDR pathophysiology and propose a promising therapeutic target.
Li et al. (Tue,) reported a other. ANGPTL4 is elevated in the vitreous humor of patients with proliferative diabetic retinopathy who do not respond to anti-VEGF therapy, suggesting a novel therapeutic target.